LeMaitre Vascular (LMAT) Set to Announce Quarterly Earnings on Wednesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.6860 per share and revenue of $67.39 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 EPS. On average, analysts expect LeMaitre Vascular to post $2.89 EPS for the current fiscal year and $3.18 EPS for the next fiscal year.

LeMaitre Vascular Stock Up 0.5%

Shares of LMAT traded up $0.40 during mid-day trading on Wednesday, reaching $84.19. The company’s stock had a trading volume of 12,288 shares, compared to its average volume of 274,399. The business has a fifty day moving average of $81.17 and a 200 day moving average of $94.21. The company has a market cap of $1.93 billion, a price-to-earnings ratio of 29.53 and a beta of 0.48. LeMaitre Vascular has a 1 year low of $78.22 and a 1 year high of $118.01.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wells Fargo & Company reduced their target price on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 5th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.